Recently, the team of Caolong Li and Fei Wang from the School of Science of CPU published the latest research results on early diagnosis of cancer in the internationally renowned journal Biosensor and Bioelectronics (IF: 12.6). The article titled “Cheap and portable paper chip with terrific oxidase-likeactivity and SERS enhancement performance for SERS-colorimetric bimodal detection of intracellular glutathione.” Is co-first authored by Linjie Wang, a 2021 Ph.D. student, and Yixin Chen, a 2021 master's student. Professor Caolong Li and Associate Professor Fei Wang are the co-corresponding authors of this paper, and China Pharmaceutical University is the only corresponding unit.
Accurate and efficient monitoring of disease biomarkers is essential for early screening, timely treatment, and postoperative monitoring of cancer. As the most abundant inhibitor of non-protein sulfhydryl oxidation in cells, glutathione plays an important role in maintaining the relative stability of various life activities. Abnormal expression of intracellular glutathione is often closely related to the occurrence of many serious diseases such as Alzheimer's disease, immune dysfunction, liver damage, and even malignant tumors. Therefore, quantitative monitoring of intracellular glutathione is of great significance for human health. Based on this, the research group has developed an inexpensive and portable paper-based chip with excellent oxidase-like activity and SERS enhancement performance for SERS-colorimetric dual-mode detection of intracellular glutathione and accurate identification of cancer cells, which provides new insights for the design and development of multimodal biosensors for early diagnosis of diseases.
In recent years, the research team of Caolong Li has carried out a series of research work in the fields of precise screening of biomolecules and the development and application of early tumor diagnosis technology, and has achieved numerous research results. Electrochemical immunobiosensors, electrochemical/colorimetric dual-mode integrated microfluidic devices, and SERS biosensors for the early diagnosis of pheochromocytoma have been reported successively (Anal. Chem. 2021, 1c01977； Biosens. Bioelectron. 2022，114208； Anal. Chim. Acta 2023, 341148). At the same time, a smartphone-assisted miniaturized optical sensing device has been developed to provide a powerful and efficient tool for the early diagnosis of prostate cancer (Sens. Actuators, B 2023, 134461; Microchim. Acta 2023, 157）.
At present, this research work is funded by the Tibet Autonomous Region Science and Technology Program (XZ202301YD0018C).
Citations
https://doi.org/10.1016/j.bios.2023.115817
